Philip James Wealth Mangement LLC Lowers Stock Position in Organon & Co. $OGN

Philip James Wealth Mangement LLC cut its stake in shares of Organon & Co. (NYSE:OGN) by 48.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 229,230 shares of the company’s stock after selling 214,942 shares during the period. Philip James Wealth Mangement LLC owned approximately 0.09% of Organon & Co. worth $1,644,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in OGN. GAMMA Investing LLC boosted its position in shares of Organon & Co. by 22.4% in the 3rd quarter. GAMMA Investing LLC now owns 6,910 shares of the company’s stock valued at $74,000 after purchasing an additional 1,265 shares during the period. Rexford Capital Inc. increased its position in Organon & Co. by 14.9% during the third quarter. Rexford Capital Inc. now owns 11,380 shares of the company’s stock worth $122,000 after buying an additional 1,480 shares during the period. Amalgamated Bank increased its position in Organon & Co. by 1.9% during the third quarter. Amalgamated Bank now owns 79,805 shares of the company’s stock worth $852,000 after buying an additional 1,514 shares during the period. Integrated Wealth Concepts LLC lifted its stake in Organon & Co. by 2.8% in the third quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after buying an additional 1,594 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in shares of Organon & Co. by 2.2% in the third quarter. Arizona State Retirement System now owns 76,924 shares of the company’s stock valued at $822,000 after acquiring an additional 1,644 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Stock Down 0.1%

OGN stock opened at $6.35 on Friday. The stock has a market capitalization of $1.65 billion, a PE ratio of 8.95, a price-to-earnings-growth ratio of 0.59 and a beta of 0.67. The company has a fifty day moving average of $7.14 and a 200-day moving average of $7.90. The company has a debt-to-equity ratio of 11.47, a quick ratio of 1.23 and a current ratio of 1.82. Organon & Co. has a one year low of $5.69 and a one year high of $14.70.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). The firm had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.52 billion. Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The company’s revenue was down 5.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.90 earnings per share. As a group, analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Monday, February 23rd were given a dividend of $0.02 per share. The ex-dividend date was Monday, February 23rd. This represents a $0.08 annualized dividend and a yield of 1.3%. Organon & Co.’s payout ratio is presently 11.27%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on OGN. Wall Street Zen lowered shares of Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Barclays upped their price target on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research report on Tuesday, February 24th. Finally, Zacks Research cut shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat, Organon & Co. currently has an average rating of “Reduce” and an average price target of $8.50.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.